presented the results of a Phase II RCT evaluating a Jak inhibitor with selectivity ... Treatment for rheumatoid arthritis (RA) has evolved over the last 15 years with early aggressive treatment ...

Positive data in December from Rigel Pharmaceuticals' phase 2 trial of R788, an oral rheumatoid arthritis ... an inhibitor of a cytoplasmic (or 'non–membrane associated') tyrosine kinase ...

Eli Lilly has opted to end a phase 2 rheumatoid arthritis (RA ... to end phase 2 trials of its selective Bruton’s tyrosine kinase (BTK) inhibitor LY3337641/HM71224 in RA. Interim results ...

An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first ...

Advances in knowledge of the pathogenesis of rheumatoid ... Of the kinase inhibitors in the drug development pipeline, the upstream Janus kinase (JAK) and spleen tyrosine kinase (Syk) targets ...

The use of JAK vs TNF inhibitors shows no significant increase in the incidence of major adverse cardiovascular events in ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood ...

inhibitor tofacitinib (Xeljanz) with an investigational oral drug targeting a different type of kinase enzyme was more effective against rheumatoid arthritis (RA) than tofacitinib alone in a phase ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood ...